메뉴 건너뛰기




Volumn 25, Issue 12, 2009, Pages 2887-2894

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: An open-label, multinational RCT

Author keywords

Biphasic insulin aspart; Glycemic control; Hypoglycemia; Insulin glargine; Once daily; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT;

EID: 72549114224     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903354674     Document Type: Article
Times cited : (74)

References (17)
  • 1
    • 77649091668 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus
    • American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl. 1):1-68
    • (2007) Endocr Pract , vol.13 , Issue.SUPPL. 1 , pp. 1-68
  • 2
    • 64749100501 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 3
    • 0034117810 scopus 로고    scopus 로고
    • Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
    • Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23(5):644-649 (Pubitemid 30321545)
    • (2000) Diabetes Care , vol.23 , Issue.5 , pp. 644-649
    • Heinemann, L.1    Linkeschova, R.2    Rave, K.3    Hompesch, B.4    Sedlak, M.5    Heise, T.6
  • 4
    • 0033661254 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro
    • Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49(12):2142-2148
    • (2000) Diabetes , vol.49 , Issue.12 , pp. 2142-2148
    • Lepore, M.1    Pampanelli, S.2    Fanelli, C.3
  • 5
    • 0142138134 scopus 로고    scopus 로고
    • Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
    • DOI 10.1016/S1056-8727(03)00076-X
    • Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17(6):307-313 (Pubitemid 37315939)
    • (2003) Journal of Diabetes and Its Complications , vol.17 , Issue.6 , pp. 307-313
    • Kilo, C.1    Mezitis, N.2    Jain, R.3    Mersey, J.4    McGill, J.5    Raskin, P.6
  • 6
    • 33646014162 scopus 로고    scopus 로고
    • Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)
    • Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8(1):58-66
    • (2006) Diabetes Obes Metab , vol.8 , Issue.1 , pp. 58-66
    • Garber, A.J.1    Wahlen, J.2    Wahl, T.3
  • 7
    • 0034694856 scopus 로고    scopus 로고
    • Ethical principles for medical research involving human subjects
    • World Medical Association Declaration of Helsinki
    • World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000;284(23):3043-3045
    • (2000) JAMA , vol.284 , Issue.23 , pp. 3043-3045
  • 9
    • 33645097582 scopus 로고    scopus 로고
    • Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience
    • Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res 2006;15(3):481-491
    • (2006) Qual Life Res , vol.15 , Issue.3 , pp. 481-491
    • Brod, M.1    Skovlund, S.E.2    Wittrup-Jensen, K.U.3
  • 12
    • 12844265257 scopus 로고    scopus 로고
    • Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs
    • DOI 10.2337/diacare.28.2.260
    • Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28(2):260-265 (Pubitemid 40170923)
    • (2005) Diabetes Care , vol.28 , Issue.2 , pp. 260-265
    • Raskin, P.1    Allen, E.2    Hollander, P.3    Lewin, A.4    Gabbay, R.A.5    Hu, P.6    Bode, B.7    Garber, A.8
  • 13
    • 66149131064 scopus 로고    scopus 로고
    • Diabetes in Asia: Epidemiology, risk factors, and pathophysiology
    • Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301(20):2129-2140
    • (2009) JAMA , vol.301 , Issue.20 , pp. 2129-2140
    • Chan, J.C.1    Malik, V.2    Jia, W.3
  • 15
    • 39049105019 scopus 로고    scopus 로고
    • A randomised, 52-week, treat-totarget trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
    • Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-totarget trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51(3):408-416
    • (2008) Diabetologia , vol.51 , Issue.3 , pp. 408-416
    • Rosenstock, J.1    Davies, M.2    Home, P.D.3
  • 16
    • 0242269000 scopus 로고    scopus 로고
    • The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
    • DOI 10.2337/diacare.26.11.3080
    • Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080-3086 (Pubitemid 37339502)
    • (2003) Diabetes Care , vol.26 , Issue.11 , pp. 3080-3086
    • Riddle, M.C.1    Rosenstock, J.2    Gerich, J.3
  • 17
    • 0021878973 scopus 로고
    • Nocturnal hypoglycaemia in patients receiving conventional treatment with insulin
    • Pramming S, Thorsteinsson B, Bendtson I, et al. Nocturnal hypoglycaemia in patients receiving conventional treatment with insulin. Br Med J (Clin Res Ed) 1985;291(6492):376-379 (Pubitemid 15012998)
    • (1985) British Medical Journal , vol.291 , Issue.6492 , pp. 376-379
    • Pramming, S.1    Thorsteinsson, B.2    Bendtson, I.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.